Physician profile
Harpreet Kaur
NPI 1831482439
$3,214.72
in general payments reported to CMS, 2019-2025
30 companies · $50.50 in 2025
The $50.50 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $316 · 2021: $314 · 2022: $761 · 2023: $570 · 2024: $484 · 2025: $50.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $557.02 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $531.49 | 2019-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $299.16 | 2021-2025 | |
| Lilly USA, LLC | $268.81 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Alexion Pharmaceuticals, INC. | $227.70 | 2019-2024 | Ultomiris, Soliris |
| Biogen, INC. | $151.28 | 2019-2021 | |
| Emd Serono, INC. | $132.33 | 2019-2024 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $122.77 | 2021-2022 | |
| Celgene Corporation | $111.31 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $90.32 | 2023 | Gammagard |
| Allergan, INC. | $79.97 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $77.18 | 2023 | Aptiom |
| Corium, LLC | $76.95 | 2023 | Adlarity |
| Amgen INC. | $70.26 | 2022-2023 | Aimovig |
| Ucb, INC. | $53.04 | 2020-2023 | Nayzilam |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $48.66 | 2019-2022 | |
| Kyowa Kirin, INC. | $42.15 | 2019-2024 | Nourianz |
| Csl Behring | $37.59 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $26.91 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $24.97 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.74 | 2019 | |
| Ge Healthcare | $21.49 | 2019 | |
| Merz Pharmaceuticals, LLC | $21.08 | 2023 | Xeomin |
| Eisai INC. | $19.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.19 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.44 | 2020 | |
| Avion Pharmaceuticals | $16.50 | 2022 | |
| Pfizer INC. | $16.46 | 2024 | |
| Vertical Pharmaceuticals, LLC | $15.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harpreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.